Balance Sheet
Cash Flow Statement
AmortizationBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Amortization (2023 - 2025)

Historic Amortization for Abivax (ABVX) over the last 3 years, with Q3 2025 value amounting to $86.5 million.

  • Abivax's Amortization fell 3090.72% to $86.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.5 million, marking a year-over-year decrease of 3090.72%. This contributed to the annual value of $116.7 million for FY2024, which is 4488.91% up from last year.
  • Abivax's Amortization amounted to $86.5 million in Q3 2025, which was down 3090.72% from $151.7 million recorded in Q1 2025.
  • In the past 5 years, Abivax's Amortization ranged from a high of $151.7 million in Q1 2025 and a low of $80.1 million during Q4 2023
  • Over the past 3 years, Abivax's median Amortization value was $116.7 million (recorded in 2024), while the average stood at $112.0 million.
  • In the last 5 years, Abivax's Amortization skyrocketed by 4566.71% in 2024 and then plummeted by 3090.72% in 2025.
  • Quarter analysis of 3 years shows Abivax's Amortization stood at $80.1 million in 2023, then surged by 45.67% to $116.7 million in 2024, then fell by 25.89% to $86.5 million in 2025.
  • Its last three reported values are $86.5 million in Q3 2025, $151.7 million for Q1 2025, and $116.7 million during Q4 2024.